Skip to main content


Blinatumomab is a prescription immunotherapy indicated for certain patients with B-cell precursor acute lymphoblastic leukemia (ALL), including specific relapsed or refractory cases, as determined by a qualified hematologist. It is a bispecific T-cell engager that connects CD19-positive leukemia cells with CD3-positive T cells, helping the immune system target malignant cells. Treatment is administered as a continuous intravenous infusion in a specialized medical setting with careful monitoring throughout therapy. In India, blinatumomab is supplied only against a valid medical prescription and in accordance with applicable regulatory and institutional treatment guidelines.


Comments